MedComm · Published 2026-06-30 · DOI 10.1002/mco2.70837
Jian Liu, Xinyan Wu, Ting Yin, Feining Huang, Manqi Kong, Yu Yang, Zinan Liu, Jiabin Yu, Tianpeng Zhang
ABSTRACT Epilepsy is a common neurological disorder with a substantial global burden. Despite major advances in diagnosis and therapy, nearly one‐third of patients remain resistant to antiseizure medications, highlighting persistent gaps in understanding epileptogenesis and disease progression. Here, we review epidemiological evidence, time‐dependent seizure patterns, and pathogenic mechanisms that contribute to epilepsy. We discuss how genetic variants, ion‐channel dysfunction, altered synaptic transmission, neuroinflammation, metabolic and mitochondrial stress, structural remodeling, network reorganization, and epigenetic regulation converge to destabilize neural circuits. These processes interact across disease stages and promote persistent hyperexcitability. We further summarize how mechanistic advances are reshaping clinical management, including precision diagnostics, pharmacotherapy, surgery, neuromodulation, dietary and lifestyle intervention, chronotherapy, biomarker‐guided stratification, and emerging disease‐modifying approaches such as immunotherapy, pathway‐targeted treatment, RNA‐based therapeutics, and gene‐directed strategies. Data‐driven tools for seizure detection and forecasting are also discussed as complementary approaches for individualized care. Overall, current evidence supports a shift from empirical seizure suppression toward mechanism‐guided and individualized care. Future progress will require closer integration of molecular discovery, validated biomarkers, and real‐world implementation to achieve earlier, more equitable, and potentially disease‐modifying treatment.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Liu, J., Wu, X., Yin, T., et al. (2026). Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management. MedComm. https://doi.org/10.1002/mco2.70837